Bilbao A, Spanagel R (2022) Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med 20(1):259

Article  PubMed  PubMed Central  Google Scholar 

Burgos B, Cigarroa I, Toloza-Ramírez D (2023) Effectiveness and safety profile of oral cannabis preparations for the treatment of refractory epilepsies in infant-young population: a scoping review. Rev Ecuat Neurol 32(1):62–74

Google Scholar 

Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10(1):101–129

Article  Google Scholar 

Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D (2014) Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55(6):791–802. https://doi.org/10.1111/epi.12631

Article  CAS  PubMed  PubMed Central  Google Scholar 

Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S (2017) Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 376(21):2011–2020

Article  CAS  PubMed  Google Scholar 

Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM (2018) Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 378(20):1888–1897. https://doi.org/10.1056/NEJMoa1714631

Article  CAS  PubMed  Google Scholar 

de Carvalho Reis R, Almeida KJ, da Silva Lopes L, de Melo Mendes CM, Bor-Seng-Shu E (2020) Efficacy and adverse event profile of cannabidiol and medicinal cannabis for treatment-resistant epilepsy: systematic review and meta-analysis. Epilepsy Behav 102:106635

Article  PubMed  Google Scholar 

Del Pozo A, Barker-Haliski M (2023) Cannabidiol reveals a disruptive strategy for 21st century epilepsy drug discovery. Exp Neurol 360:114288

Article  PubMed  Google Scholar 

Elliott J, DeJean D, Clifford T, Coyle D, Potter BK, Skidmore B, Alexander C, Repetski AE, Shukla V, McCoy B, Wells GA (2019a) Cannabis-based products for pediatric epilepsy: a systematic review [article]. Epilepsia 60(1):6–19. https://doi.org/10.1111/epi.14608

Article  PubMed  Google Scholar 

Elliott J, McCoy B, Clifford T, Potter BK, Skidmore B, Wells GA, Coyle D (2019b) Cost-effectiveness of cannabinoids for pediatric drug-resistant epilepsy: protocol for a systematic review of economic evaluations. Syst Rev 8:1–5

Article  Google Scholar 

Elliott J, DeJean D, Clifford T, Coyle D, Potter BK, Skidmore B, Alexander C, Repetski AE, Shukla V, McCoy B (2020) Cannabis-based products for pediatric epilepsy: an updated systematic review. Seizure 75:18–22

Article  PubMed  Google Scholar 

Fazlollahi A, Zahmatyar M, ZareDini M, Golabi B, Nejadghaderi SA, Sullman MJ, Gharagozli K, Kolahi A-A, Safiri S (2023) Adverse events of cannabidiol use in patients with epilepsy: a systematic review and meta-analysis. JAMA Netw Open 6(4):e239126–e239126

Article  PubMed  PubMed Central  Google Scholar 

FDA Approval of CBD (2018) https://www.jazzpharma.com/

Franco V, Bialer M, Perucca E (2021) Cannabidiol in the treatment of epilepsy: current evidence and perspectives for further research. Neuropharmacology 185:108442. https://doi.org/10.1016/j.neuropharm.2020.108442

Article  CAS  PubMed  Google Scholar 

Friedman D, Devinsky O (2015) Cannabinoids in the treatment of epilepsy. N Engl J Med 373(11):1048–1058

Article  CAS  PubMed  Google Scholar 

Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924–926

Article  PubMed  PubMed Central  Google Scholar 

Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, Paolini JL, Thiele EA (2016) Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia 57(10):1617–1624. https://doi.org/10.1111/epi.13499

Article  CAS  PubMed  Google Scholar 

Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558

Article  PubMed  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560

Article  PubMed  PubMed Central  Google Scholar 

IbeasBih C, Chen T, Nunn AV, Bazelot M, Dallas M, Whalley BJ (2015) Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics 12(4):699–730. https://doi.org/10.1007/s13311-015-0377-3

Article  CAS  Google Scholar 

Lattanzi S, Brigo F, Cagnetti C, Trinka E, Silvestrini M (2018a) Efficacy and safety of adjunctive cannabidiol in patients with Lennox-Gastaut syndrome: a systematic review and meta-analysis. CNS Drugs 32(10):905–916. https://doi.org/10.1007/s40263-018-0558-9

Article  CAS  PubMed  Google Scholar 

Lattanzi S, Brigo F, Trinka E, Zaccara G, Cagnetti C, Del Giovane C, Silvestrini M (2018b) Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis [review]. Drugs 78(17):1791–1804. https://doi.org/10.1007/s40265-018-0992-5

Article  CAS  PubMed  Google Scholar 

Lattanzi S, Brigo F, Trinka E, Zaccara G, Striano P, Del Giovane C, Silvestrini M (2020) Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety [review]. CNS Drugs 34(3):229–241. https://doi.org/10.1007/s40263-020-00708-6

Article  CAS  PubMed  Google Scholar 

Liu S, He Z, Li J (2023a) Long-term efficacy and adverse effects of cannabidiol in adjuvant treatment of drug-resistant epilepsy: a systematic review and meta-analysis. Ther Adv Neurol Disord 16:17562864231207756. https://doi.org/10.1177/17562864231207755

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu S, He Z, Li J (2023b) Long-term efficacy and adverse effects of cannabidiol in adjuvant treatment of drug-resistant epilepsy: a systematic review and meta-analysis. Ther Adv Neurol Disord 16:17562864231207756

Article  CAS  PubMed  PubMed Central  Google Scholar 

Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, Saneto RP, Checketts D, Dunayevich E, Knappertz V (2020) Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in Dravet syndrome: a randomized clinical trial. JAMA Neurol 77(5):613–621. https://doi.org/10.1001/jamaneurol.2020.0073

Article  PubMed  Google Scholar 

Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & Group, P.-P (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1–9

Article  Google Scholar 

Organization, W. H. (2024). Epilepsy. https://www.who.int/news-room/fact-sheets/detail/epilepsy

Pamplona FA, da Silva LR, Coan AC (2018) Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis. Front Neurol 9:759. https://doi.org/10.3389/fneur.2018.00759

Article  PubMed  PubMed Central  Google Scholar 

Pharmaceuticals J (2018) Epidiolex prescribing information. Jazz Pharmaceuticals, Inc. Retrieved January 13 from https://urlis.net/8j1q2f9s

Reuben A (2004) Hy’s law. Hepatology 39(2):574–578

Article  PubMed  Google Scholar 

Samanta D (2022) A scoping review on cannabidiol therapy in tuberous sclerosis: current evidence and perspectives for future development. Epilepsy Behav 128:108577

Article  PubMed  Google Scholar 

Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E (2017) AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. https://doi.org/10.1136/bmj.j4008

Article  PubMed  PubMed Central